Edgar Filing: IDERA PHARMACEUTICALS, INC. - Form 4

IDERA PHARMACEUTICALS, INC. Form 4 December 04 2007

December 0	4,2007									
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION								OMB APPROVAL		
	UNITED	STATES		RITIES A shington			E COMMISSIO	N OMB Number:	3235-0287	
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box if no longer STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							Estimated burden hoi response	urs per		
(Print or Type	Responses)									
1. Name and A Arcudi Lou	Address of Reporting is J.	Person <u>*</u>	Symbol	er Name and A PHARM DP]		-	5. Relationship (Issuer (Cho	of Reporting Per eck all applicabl		
(Last) 167 SIDNE	(First) (A	Middle)		of Earliest T Day/Year) 2007	ransaction		Director X Officer (gi below) Chie		% Owner her (specify cer	
CAMBRID	(Street) GE, MA 02139			endment, D onth/Day/Yea	-	al		-	erson	
(City)	(State)	(Zip)	Π.Ι.	L T No. I		G	Person	. f D f	1 0	
							Acquired, Disposed		-	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	С
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

Edgar Filing: IDERA PHARMACEUTICALS, INC. - Form 4

(Instr. 3)	Price of Derivative Security			· ·	(Instr. 3, 4,				
			Code V	(A) (D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Options	\$ 12.25	12/03/2007	А	80,000	<u>(1)</u>	12/03/2017	Common Stock	80,000	

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Arcudi Louis J. 167 SIDNEY STREET CAMBRIDGE, MA 02139			Chief Financial Officer				

Signatures

Louis J. Arcudi III 12/03/2007 **Signature of Date Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) One-third of the shares will vest on 12/03/2008 and the remaining two-thirds will vest in equal quarterly installments beginning on 3/03/2009 and continuing until 12/03/2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.